Genomes2Peoples study on personal genetic testing proved to be very beneficial for adoptees that were curious about their family genetic history.
Direct-to-consumer genetic testing has brought people into doctors offices for second opinions or possible referrals for preventive medicine about potential conditions found when receiving back their results. What patients are finding is that many physicians are skeptical about the use of genetic testing in most cases.
The principal investigators on the BabySeq project were trying to determine what information would be the most pertinent and helpful for both patients and physicians to know from whole-exome sequencing in the initial stages of the project. Their findings within the first couple of patients were quite interesting and they are excited to continue with … Continued
In November 2013, the FDA publicly ordered 23andMe to cease sales. A few years later, 23andMe rebranded to offer only some health reports along with ancestry and genealogy reports, without the serious health indicators it initially had in mind. The company is working its way back to providing medical information.
The big question is how to make genomic information useful to patients and medical practitioners; Genomes2People is looking for answers through the MedSeq and BabySeq projects, among others.
Dr. Robert Green, Director of G2P research at Brigham and Women’s and Harvard Medical, speaks with Front Line Genomics about his initial interest and how his career has flourished into what it is today, including over 300 papers written and published and recognition in one of the leading fields of medicine.
After a consumer uses direct personalized genomic testing, they have an option to bring those result to a physicians office. While there is still much skepticism toward direct-to-consumer testing, many doctors dismiss the entirely of the results, while other physicians are more open to using the results to work on personal health for their patients.